

Erratum

In the article “Quantification of Task-Specific Glucose Metabolism with Constant Infusion of ^{18}F -FDG” by Hahn et al. (*J Nucl Med.* 2016;57:1933–1940), the absolute values of CMRGlu in Table 1 are lower than initially reported because of a cross-calibration error. Because this was a systematic scaling error, the statistics and interpretations remain unchanged. The authors regret the error.

TABLE 1
Task-Specific Changes in Glucose Metabolism for Eyes-Open Condition and Right-Finger Tapping as Compared with Baseline

Region	x (mm)	y (mm)	z (mm)	t value	CMRGlu baseline ($\mu\text{mol}/100\text{ g}/\text{min}$)	CMRGlu task ($\mu\text{mol}/100\text{ g}/\text{min}$)	Signal change (%)
Eyes open > baseline							
Lingual L	-4	-88	-14	10.4*	25.6 ± 4.4	0.9 ± 0.4	3.6 ± 1.4
Intracalcarine L	-8	-84	8	10.0*	25.7 ± 4.2	0.8 ± 0.3	3.0 ± 1.1
Supracalcarine R	16	-66	14	10.4*	28.3 ± 4.6	0.6 ± 0.2	2.2 ± 0.8
Occipital pole R	8	-96	-8	9.8*	23.7 ± 5.3	0.9 ± 0.4	4.0 ± 1.9
Cuneus	0	-82	26	11.8*	27.6 ± 4.2	0.6 ± 0.2	2.3 ± 0.8
Cerebellum crus II L	-12	-88	-24	17.2*	20.8 ± 3.4	1.3 ± 0.4	6.1 ± 1.7
Cerebellum crus II R	8	-80	-28	9.4*	21.9 ± 3.5	1.2 ± 0.6	5.5 ± 2.2
Cerebellum VI L	-28	-54	-28	16.5*	22.5 ± 3.2	0.7 ± 0.2	3.1 ± 0.8
Cerebellum crus I L	-26	-88	-30	11.9*	15.7 ± 2.9	0.6 ± 0.3	4.0 ± 1.5
Cerebellum crus I R	52	-52	-34	12.9*	15.4 ± 2.9	0.9 ± 0.3	5.8 ± 1.8
Cerebellum vermis IX L	-2	-54	-30	11.8*	17.1 ± 2.4	0.7 ± 0.3	4.2 ± 1.5
Hippocampus L	-30	-18	-12	9.7*	16.3 ± 2.4	0.8 ± 0.3	5.2 ± 2.2
Eyes open < baseline							
Frontal superior L	-18	32	46	-9.2*	27.9 ± 5.3	-0.6 ± 0.3	-1.9 ± 0.8
Central L	-40	-24	58	-0.7	27.6 ± 4.3	-0.1 ± 0.6	-0.4 ± 2.2
Finger tapping > baseline							
Central L	-40	-24	58	11.5*	27.6 ± 4.3	1.8 ± 0.8	6.3 ± 2.8
Precentral L	-32	-16	70	10.7*	19.0 ± 3.5	1.1 ± 0.6	5.7 ± 2.5
Hippocampus L	-28	-16	-12	12.1*	16.3 ± 2.5	0.9 ± 0.4	5.6 ± 1.9
Cerebellum VI L	-32	-56	-26	13.0*	24.8 ± 3.5	1.1 ± 0.3	4.3 ± 1.3
Cerebellum VI R	8	-64	-10	11.3*	21.8 ± 2.9	0.8 ± 0.4	3.5 ± 1.3
Cerebellum crus I R	52	-52	-32	9.4*	16.6 ± 3.3	0.8 ± 0.4	5.0 ± 2.2
Finger tapping < baseline							
Intracalcarine L	-8	-84	8	-0.8	25.7 ± 4.2	-0.1 ± 0.6	-0.3 ± 2.3

* $P < 0.05$, FWE-corrected voxel level.

Significance thresholds were $t = 8.7$ for $P < 0.05$, FWE-corrected, and $t = 3.8$ for $P < 0.001$, uncorrected. Coordinates and t values were obtained from SPM analysis. Corresponding CMRGlu as obtained from Patlak plot is shown for baseline condition and each task as well as percentage signal changes from baseline.

Erratum

There is an error in the financial disclosure of “Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions” by Deroose et al. (*J Nucl Med.* 2016;57:1949–1956). The correct disclosure is as follows: “Dr. Deroose is a consultant/advisor for Sirtex and Ipsen, is a meeting participant/lecturer for Bayer, and is involved in a scientific study/trial for Advanced Accelerator Applications (AAA). AAA (^{68}Ga -DOTATATE, ^{177}Lu -DOTATATE, ^{18}F -DOPA, and ^{18}F -FDG), Sirtex (selective internal radiotherapy spheres), and Ipsen (lanreotide and radiolabeled SSTR antagonists) produce diagnostic and therapeutic agents described in this article.” The authors regret the error.